Cancer/testis antigen 1 (87-111)

Cancer/testis antigen 1 (87-111) is a synthetic peptide fragment derived from the immunodominant region of the cancer/testis antigen 1 (CTAG1), also known as NY-ESO-1. This peptide corresponds to amino acids 87 through 111 of the full-length protein, a region recognized for its strong immunogenic properties and restricted expression profile, predominantly found in various malignancies and germ cells of the testis. Owing to its unique pattern of expression and antigenic potential, the 87-111 epitope is a valuable tool for immunological studies, cancer immunotherapy research, and the development of peptide-based assays. Its defined sequence and established immunoreactivity make it particularly relevant for applications focused on tumor antigen discovery, immune monitoring, and T-cell epitope mapping.

Epitope mapping: The 87-111 peptide fragment is frequently employed in epitope mapping experiments to delineate the specific regions of CTAG1 recognized by T cells or antibodies. By using this defined segment, researchers can systematically identify immunologically active domains within the parent antigen, facilitating the characterization of T-cell receptor (TCR) specificity and the assessment of immune recognition in cancer models. These studies are instrumental in understanding the molecular basis of antigenicity and in refining the selection of target epitopes for further immunological investigation.

T-cell activation assays: As a well-characterized immunogenic sequence, this peptide serves as a potent stimulus in T-cell activation assays. It enables the evaluation of antigen-specific T-cell responses in vitro, such as proliferation, cytokine secretion, and cytotoxic activity, using peripheral blood mononuclear cells (PBMCs) or isolated T-cell clones from cancer patients or healthy donors. The use of this peptide in such assays aids in monitoring the magnitude and quality of cellular immune responses directed against CTAG1, providing critical insights into immune surveillance and tumor immunology.

Immunogenicity studies: Researchers utilize this peptide to assess the immunogenic potential of CTAG1-derived epitopes in preclinical models. By incorporating the 87-111 sequence into immunization protocols or ex vivo stimulation experiments, it is possible to evaluate the induction of antigen-specific immune responses, including both humoral and cellular arms. Such studies contribute to the understanding of antigen processing, presentation, and the mechanisms underlying immune recognition of tumor antigens, supporting the rational design of cancer vaccines and immunotherapeutic strategies.

Peptide-based assay development: The defined sequence and immunoreactivity of the 87-111 fragment make it an excellent candidate for the development of peptide-based immunoassays, including enzyme-linked immunospot (ELISpot) and enzyme-linked immunosorbent assays (ELISA). These assays are employed to detect and quantify antigen-specific T cells or antibodies in biological samples, facilitating immune monitoring in clinical research settings. Incorporation of this peptide into assay platforms enhances sensitivity and specificity for CTAG1-targeted immune responses, aiding in the evaluation of immunotherapeutic efficacy and disease monitoring.

Structural and binding studies: In addition to immunological applications, the 87-111 peptide is valuable in structural biology and molecular interaction analyses. It can be used to investigate peptide-MHC binding affinities, elucidate the structural determinants of epitope recognition, or serve as a probe in crystallography and biophysical assays. Such studies deepen the understanding of antigen presentation and TCR-peptide-MHC interactions, informing the design of improved immunotherapeutic agents and diagnostic tools targeting cancer/testis antigens.

1. Quantitative Analysis of Ligands Effects on Bioefficacy of Nanoemulsion encapsulating Depigmenting Active

2. An Open-label, Single-center, Safety and Efficacy Study of Eyelash Polygrowth Factor Serum

3. Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

4. Immune responses to peptides containing homocitrulline or citrulline in the DR4-transgenic mouse model of rheumatoid arthritis

5. Zeta-potential-changing nanoparticles conjugated with cell-penetrating peptides for enhanced transfection efficiency